Marshall Wace, LLP Apellis Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

$74.4 Billion
Q1 2025

A detailed history of Marshall Wace, LLP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 23,574 shares of APLS stock, worth $411,130. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,574

Previous 85,495 72.43%

Holding current value

$411,130

Previous $2.73 Million 81.12%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$21.87 - $34.63 $1.35 Million - $2.14 Million	-61,921 Reduced 72.43%	23,574 $515,000
Q4 2024 Feb 13, 2025	BUY	$26.18 - $35.42 $1.67 Million - $2.26 Million	63,705 Added 292.36%	85,495 $2.73 Million
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $628,423 - $896,658	21,790 New	21,790 $628,000
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $3.27 Million - $4.28 Million	-59,003 Reduced 25.56%	171,873 $10.1 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $2.29 Million - $3.99 Million	61,582 Added 36.38%	230,876 $13.8 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $4.09 Million - $15.4 Million	-173,058 Reduced 50.55%	169,294 $6.44 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $19.2 Million - $23.3 Million	249,906 Added 270.33%	342,352 $31.2 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $16 Million - $23 Million	-343,977 Reduced 78.82%	92,446 $6.1 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $4.31 Million - $6.09 Million	99,696 Added 29.61%	436,423 $22.6 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $46.2 Million - $71.9 Million	-1,031,680 Reduced 75.39%	336,727 $23 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $15.9 Million - $26.8 Million	453,244 Added 49.53%	1,368,407 $61.9 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $32.1 Million - $49 Million	904,788 Added 8720.85%	915,163 $46.5 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $424,337 - $673,337	10,375 New	10,375 $656,000
Q1 2019 May 14, 2019	SELL	$12.81 - $19.82 $43,323 - $67,031	-3,382 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $38,791 - $63,277	3,382 New	3,382 $45,000

Others Institutions Holding APLS

# of Institutions

295

Shares Held

124M

Call Options Held

921K

Put Options Held

761K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $1.92B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Apellis Pharmaceuticals, Inc. Transaction History